Audentes Therapeutics today announced their first quarter 2018 results. For x-linked myotubular myopathy, they reported that the next 3 patients were enrolled at the first dose level of ASPIRO, the Phase 1/2 clinical study of AT132, their gene therapy product. They confirmed that there were no significant adverse safety events in these 3 extra patients.

They plan to report additional interim data at the meeting of the American Society of Cell and Gene Therapy on May 16th, releasing 24 week data for the first four subjects in ASPIRO, and 4 week data for the second four subjects.

Read the press release here.